Gluxit Trio 5mg/1000mg/50mg Tablet

Metformin, a biguanide, primarily decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, contributing to reduced fasting and postprandial glucose concentrations. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, prolongs the activity of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner.

The combined use of these agents offers a multifaceted approach to glycemic control, addressing insulin resistance, impaired insulin secretion, and excess glucose reabsorption. Gluxit Trio is intended as adjunctive therapy to diet and exercise in patients inadequately controlled on monotherapy or dual therapy. It should be used with caution in patients with renal impairment, and regular monitoring of renal function and glycemic parameters is recommended.

Common adverse effects may include gastrointestinal disturbances, urinary tract infections, and hypoglycemia, particularly when used with other antidiabetic agents.